A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Reported in ALL

Authors

Mateo Mejia Saldarriaga, Albert Einstein College of Medicine/Jacobi Medical Center
Amir Steinberg, Mount Sinai Hospital
Eric A. Severson, Foundation Medicine, Morrisville, NC
Adam Binder, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

12-3-2019

Comments

This article is the author’s final published version in Frontiers in Oncology, Volume 9, December 2019, Article number 1303.

The published version is available at https://doi.org/10.3389/fonc.2019.01303. Copyright © Saldarriaga et al.

Abstract

We report the case of a patient with B-Cell Acute Lymphoblastic Leukemia (ALL) who was found to harbor a gene fusion involving the CCDC6 and RET genes. Although the RET mutations have been identified before in othermalignancies, and it is thought to represent a driver mutation in these neoplasms, it has yet to be described in ALL. The identification of known fusion genes conferring activating tyrosine kinase activity in neoplasms can suggest potential therapeutic role of tyrosine kinase inhibitors (TKI), an approach that has been exploited in several other fusion genes.

Recommended Citation

Saldarriaga, Mateo Mejia; Steinberg, Amir; Severson, Eric A.; and Binder, Adam, "A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Reported in ALL" (2019). Department of Medical Oncology Faculty Papers. Paper 105.
https://jdc.jefferson.edu/medoncfp/105

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English